Why Is Clover Wellness (CLOV) Stock Up Today? Director Chelsea Clinton purchased 100,000 shares of CLOV stockĀ 

Today, investors of Clover Wellness (NASDAQ: CLOV) are grinning ear to ear. Although clov stock chart remains down greater than 25% year-to-date (YTD), shares of the firm are up over 20% today.

Why exactly is Clover Wellness trading greater right now?

Over the weekend break, it was reported that Clover supervisor Chelsea Clinton had actually just recently bought shares of CLOV stock. The transaction, which took place on March 3, saw Clinton acquire 100,000 shares for an ordinary price of $2.52 per share. In overall, Clinton’s recent deal amounted to $252,530, according to a Form 4 submitted to the U.S. Stocks as well as Exchange Compensation (SEC).

Why Is CLOV Stock Up Today?
Today, CLOV stock is up in feedback to Clinton’s acquisition, which capitalists are considering as a favorable signal. Many times, supervisor trading task such as this is essential to track since experts commonly have a much better view of a firm’s long-term growth potential than retail capitalists.

So, with that said in mind, are other insiders of Clover favorable on the firm? In the past twelve month, insiders have actually purchased 2.2 million shares and offered 22.9 million shares. That’s a web of 20.6 million shares sold. This mass insider marketing seems to associate with CLOV stock’s decline of greater than 60% over the past one year.

Still, with Clinton’s recent acquisition, financiers are wondering who else is betting huge on Clover Health and wellness. Allow’s jump right in.

Who Else Is Betting Big on Clover Health?
Since the fourth quarter, 160 institutional investors own shares of CLOV stock. That notes a quarter-0ver-quarter (QOQ) rise of 8.8%. During the period, the overall amount of shares held by institutional financiers also raised from 105.7 million to 129.8 million, up almost 23% QOQ. Let’s have a look at the top 5 institutional investors.

Vanguard has 25.9 million shares or 7.65% possession. The company bought 8.8 million shares during Q4.
Greenoaks Capital Allies owns 24.8 million shares or 7.34% possession. The company sold 24.8 million shares during Q4.
Baillie Gifford has 7.8 million shares or 2.3% possession. The company purchased 2.6 million shares during Q4.
2 Sigma Investments has 6.6 million shares or 1.95% possession. The firm purchased all 6.6 million shares throughout Q4.
PNC Financial Provider (NYSE: PNC) possesses 6.4 million shares or 1.88% ownership. The company marketed 249,850 shares during Q4.
Out of the leading five investors, three funds decreased their positions and 2 funds raised their settings. Greenoaks Capital Partners had one of the most significant purchase, as the fund sold about 50% of its existing setting throughout Q4. 2 Sigma’s 6.6 million share acquisition was also significant, as the purchase put it amongst the leading five shareholders.